A PHASE 1 DOSE ESCALATION STUDY OF A NEW ALK INHIBITOR, CH5424802/RO5424802, IN ALK+ NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WHO HAVE FAILED CRIZOTINIB (AF-002JG/NP28761, NCT01588028)
JOURNAL OF THORACIC ONCOLOGY（2013）
关键词
ALK-inhibitor,Crizotinib-failure,Phase I,CH5424802
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要